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Abstract
The use of antibiotics is highest in primary care and directly associated with antibiotic resistance in the community. We assessed regio-
nal variations in antibiotic use in primary care in Switzerland and explored prescription patterns in relation to the use of point of care
tests. Deﬁned daily doses of antibiotics per 1000 inhabitants (DDD1000pd) were calculated for the year 2007 from reimbursement data
of the largest Swiss health insurer, based on the anatomic therapeutic chemical classiﬁcation and the DDD methodology recommended
by WHO. We present ecological associations by use of descriptive and regression analysis. We analysed data from 1 067 934 adults,
representing 17.1% of the Swiss population. The rate of outpatient antibiotic prescriptions in the entire population was 8.5 DDD1000pd,
and varied between 7.28 and 11.33 DDD1000pd for northwest Switzerland and the Lake Geneva region. DDD1000pd for the three most
prescribed antibiotics were 2.90 for amoxicillin and amoxicillin-clavulanate, 1.77 for ﬂuoroquinolones, and 1.34 for macrolides. Regions
with higher DDD1000pd showed higher seasonal variability in antibiotic use and lower use of all point of care tests. In regression analysis
for each class of antibiotics, the use of any point of care test was consistently associated with fewer antibiotic prescriptions. Prescrip-
tion rates of primary care physicians showed variations between Swiss regions and were lower in northwest Switzerland and in physi-
cians using point of care tests. Ecological studies are prone to bias and whether point of care tests reduce antibiotic use has to be
investigated in pragmatic primary care trials.
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Background
There is growing evidence from observational studies that
antibiotic overuse is an important risk factor for the
emergence of antibiotic resistance [1,2]. In primary care,
most antibiotics are prescribed for upper and lower
respiratory tract and urinary tract infections. Antibiotic
resistance has been recognized as an increasing public
health problem. Therefore the European Surveillance of
Antimicrobial Consumption project was established to col-
lect data on outpatient antibiotic use in a uniform format
[3]. Highly variable rates of antibiotic prescriptions were
found, with higher rates of deﬁned daily doses (DDD) in
the Mediterranean countries, compared with those in the
northern European countries. Striking seasonal ﬂuctuations
and higher rates of antibiotic resistance were observed in
particular in high-prescribing countries [3]. Switzerland has
one of the lowest rates of antibiotic consumption in
Europe [4]. Contrary to many European countries, point
of care tests are widely used by primary care providers in
Switzerland [5]. First intervention trials indicate that point
of care tests may contribute to a more diligent use of
antibiotics in primary care [6,7]. However, there is con-
ﬂicting evidence from epidemiological data of outpatient
antibiotic use in relation to the use of such tests. Based
on prescription records of the largest social health insurer,
we investigated differences in outpatient antibiotic use in
Switzerland in relation to regions, seasons and use of
point of care tests.
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Methods
We analysed reimbursement data of systemic antibiotic use
in ambulatory care from 2007 of the Helsana Group, the
largest social health insurer in Switzerland. This insurer cov-
ers, according to regions, between 11.5% and 22.8% of the
Swiss population.
Information on drug prescriptions was received from
invoices. Antibiotics were identiﬁed by the pharma code, an
index for the identiﬁcation of the drug, application form,
doses and package size used in Switzerland and provided by
e-mediat AG, Bern, Switzerland [8]. According to regions,
between 95.8% and 97.9% of invoices are sent or pro-
cessed electronically and centrally stored by the health
insurer, guaranteeing high completeness of data for the par-
ticular calendar year. All antibiotics analysed have to be
covered by the social health insurance, although individuals
with high deductibles may not send their bills to the health
insurer.
We considered only outpatient antibiotic use provided by
self-dispensing physicians or pharmacies. We classiﬁed each
antibiotic with the anatomic therapeutic chemical (ATC) clas-
siﬁcation codes [9]. We included only antibiotics with sys-
temic and oral administration and excluded all antifungals,
antimycobacterial drugs, and all topical antibiotics. For each
ATC code and drug, we calculated deﬁned daily doses
(DDD) based on the World Health Organisation (WHO)
deﬁnitions [9]. For the calculation of DDD1000 per day (pd),
the study population was standardized by age and gender.
The reference was the Swiss population of 2007 [10]. The
number of Swiss residents being insured with the Helsana
Group for the year 2007 and the total person days involved
was calculated for each region. This allowed us the calcula-
tion of the DDD per 1000 persons per day (DDD1000pd) by
summing up the DDD either per month or by year and
dividing it by the number of insured individuals for the
respective unit of time. We explored regional differences in
antibiotic use based on the seven major regions as deﬁned
by the Swiss Federal Statistical Ofﬁce (for a map see refer-
ence [11]).
We further analysed for each antibiotic prescription
whether the reimbursement claims included compensations
for ofﬁce-based point of care tests, a laboratory test or
radiographs ordered within 7 days prior to or 2 days follow-
ing the procedure date. Point of care tests included urine
analysis for leucocyte counts and urine culture, white blood
cell count, C-reactive protein (CRP), pharyngeal-smear for
antigen testing or culture of group A Streptococcus. Primary
care physicians in Switzerland may run their own radiology
facilities for conventional radiographs, or refer their patients
to radiology centres.
In Switzerland deductibles are mandatory for all patients
and according to individual budget and insurance package
may range between Swiss Francs 300–2500 per year. Patients
whose invoices are below the limit of the deductible some-
times do not send their bills to the insurance company but
pay them directly. This results in incomplete information
regarding their actual health care utilization. Therefore, we
included for this part of the analysis only patients with data
on point of care tests where the expenses exceeded the
deductible. This restriction ensures that only individuals with
complete information on antibiotic prescriptions and point of
care tests were considered for the analysis, which reduced
our number of prescriptions by 12.7%. We further restricted
our analysis of point of care tests to primary care physicians
and general internists (by excluding all specialists) and to
physicians with at least four prescriptions per antibiotic
group in order to avoid coefﬁcients with zero values. This
additional restriction reduced our initial number of prescrip-
tions for the analysis of point of care tests by another 54.1%
and resulted in a ﬁnal total of 126 048 (40.0% of all prescrip-
tions).
We used linear regression analysis to calculate the ratio
between the number of prescriptions per patient group and
the percentage of point of care tests for these prescriptions.
All patients of one physician were divided into four patient
groups according to gender and age (18–64 and >65 years).
For each antibiotic group, the outcome variable (e.g. the
number of prescriptions) divided by the number of patients
per patient group and physician was calculated. Because our
outcome variable was skewed to the left we used a log-
transformation and obtained normally distributed dependent
variables and residuals. In addition, the percentage of point
of care tests per antibiotic prescription and region was calcu-
lated for all patients with costs in excess of the deductible.
All statistical analyses were carried out with the open soft-
ware R version 2.7.
Results
This analysis is based on data from 1 067 934 Swiss residents
aged 18 or older that had mandatory health insurance with
the Helsana Group, representing 17.1% of the Swiss popula-
tion. In 2007, the mean age of this served population was
1.6 years above the national average age of 41.1 years, and
compensation costs for this population were 7.6% above the
national average [10,12]. Overall, 52.5% of the population
were female and 26% were aged over 65 years. General
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practitioners comprised 41.5%, general internists 17.3% and
specialists 41.2% of 11 208 antibiotic prescribing physicians,
with a total of 314 915 prescriptions.
The rate of outpatient antibiotic prescriptions in the
entire population was 8.5 DDD1000pd and varied by a factor
of 1.5, with the highest rate in the region of Lake Geneva
(11.33 DDD1000pd) and the lowest prescription rate in north-
west Switzerland (7.28 DDD1000pd) (Fig. 1). In general,
regions with higher overall prescription rates had also higher
prescriptions per antibiotic group, with the exception of
central Switzerland where consumption of amoxicillin and
amoxicillin-calvulanate was lower (Fig. 1). In all regions, ﬂuoro-
quinolones were the second most prescribed antibiotics,
with DDD1000pd ranging between 1.45 and 2.28. Macrolides
were the third most prescribed antibiotics, with DDD1000pd
between 1.13 (east Switzerland) and 1.94 (Lake Geneva).
Espace Midland, Lake Geneva and Ticino had a higher pre-
scription rate for other betalactams (all betalactams exclud-
ing amoxicillin and amoxicillin/clavulanate), with DDD1000pd
ranging between 0.69 and 1.29 when compared with ranges
of prescription rates of 0.34 and 0.48 DDD1000pd in the
remaining regions.
In order to explore seasonal variation we calculated mean
DDD1000pd per month according to regions and antibiotic
groups (Fig. 2). There was a high variation between summer
and winter months for amoxicillin and amoxicillin-clavulanate
for the two regions Lake Geneva and Ticino, with the high-
est prescription rates and less seasonal variation in the
remaining regions with lower overall prescriptions for amox-
icillin and amoxicillin-clavulanate. We found a very similar
pattern for macrolides and other betalactam antibiotics,
although the absolute difference in seasonal prescription vari-
ation was lower for theses groups of antibiotics.
Table 1 shows the use of point of care tests according to
regions. We found a consistent pattern for each antibiotic,
with a higher use of point of care tests in regions with lower
antibiotic use. The use of all point of care tests was highest
in the northwest, northeast and the Zurich regions and low-
est in the Ticino and Lake Geneva regions. In a further analy-
sis, we modelled the ratio of the number of prescriptions
divided by the number of patients per physician and groups
of antibiotics in relation to the use of point of care tests.
The use of a point of care test was for all antibiotics consis-
tently associated with fewer antibiotic prescriptions
(Table 2). For example, if physicians conducted any point of
care test the number of antibiotic prescriptions for amoxicil-
lin and amoxicillin-clavulanate and ﬂuoroquinolones was
reduced by a factor of 0.79 (95% CI, 0.74–0.84) and 0.68
FIG. 1. Standardized DDD per 1000 inhabitants per day, for outpatient prescriptions in 2007 for all antibiotics and selected antibiotics for seven
Swiss regions and Switzerland. Measures are standardized for age and sex to the Swiss population. NW, northwest; CH, Switzerland.
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(95% CI, 0.65–0.72%), respectively. Thus, the use of point of
care tests was associated with a 21% (95% CI, 16–26%) and
32% (95% CI, 28–45%) reduction in prescriptions of these
antibiotics. With the exception of ﬂuoroquinolones, female
patients were less likely to receive an antibiotic prescription
for each antibiotic class. Age was consistently associated with
a higher use of antibiotics for each antibiotic class. The vari-
ance of antibiotic prescriptions and drug class explained by
our model, however, was modest (adjusted R2).
Discussion
In this study, data from roughly one-ﬁfth of the adult Swiss
population are represented. We conﬁrm a very low rate of
outpatient antibiotic prescriptions with important variation
between regions within Switzerland. Overall DDD1000pd
were highest for the French and Italian speaking parts (Lake
Geneva and Ticino) of Switzerland. However, rates in these
regions were still in the range of low prescribing European
countries such as the Netherlands [3]. Similar to the pattern
in other European countries, we found a higher seasonal var-
iation of antibiotic prescriptions in high prescribing regions.
Amoxicillin and amoxicillin-clavulanate continue to be the
most used antibiotics for outpatients in Switzerland [4]. Use
of macrolids and ﬂuoroquinolones, however, is relatively high
in Switzerland and constitutes a known risk factor for antibi-
otic resistance, in particular for S. pneumoniae [13–15].
Increased use of amoxicillin-clavulanate and ﬂuoroquinolones
has also been noted in other European countries [16]. We
found a consistent inverse relation between use of any point
of care test and antibiotic prescriptions for all classes of anti-
biotics that are mostly used in upper and lower respiratory
tract and urinary tract infections.
This study has several strengths. Contrary to other stud-
ies, we used a single and rather comprehensive data source
for antibiotic use from the reimbursement system of the
largest Swiss social health insurer. This source guarantees a
uniform data collection system that is based on information
on drug use for antibiotics that were actually delivered to
patients. Thus, our analysis is not based on data of drug sales
as used in previous studies [3,4], which may introduce bias
in ecological analyses [3,17]. In addition, our database
allowed us to identify the prescription behaviour at the indi-
vidual physician level. We used the ATC classiﬁcation system
and report DDD measurement units in standardized formats
FIG. 2. Monthly average DDD per 1000 inhabitants per day, for outpatient prescriptions in 2007 for seven regions in Switzerland. For better
visibility of seasonal ﬂuctuations the ﬁrst month shown is April 2007 (A) and the last month shown is March 2007 (M). Measures are standard-
ized for gender and age to the Swiss standard population. NW, northwest; CH, Switzerland.
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that allow for comparison of our data with other countries
[9]. We restricted our analysis to adults in order to avoid
bias, because DDDs do not take into account different doses
for children.
We could show an important and statistically signiﬁcant
reduction in the range of 21% to 37% for prescriptions of
the ﬁve most frequently used classes of antibiotics with the
use of any point of care test. Although these ﬁndings are
important and interesting from the public health perspective,
they have to be interpreted with caution. No causal associa-
tion can be drawn from our ecological study. Our ﬁndings
could be confounded by other factors related to physicians
or patients we were unable to measure. Physicians who use
more tests may reassure patients and themselves that antibi-
otics are not needed. In a primary care study on patients’
expectations for antibiotics in respiratory tract infections,
reassurance was more strongly related to patient satisfaction
than actually receiving an antibiotic prescription [18]. Thus,
the association of lower antibiotic prescription rates with
the use of point of care tests could simply reﬂect testing
patients with low probability of bacterial infection. As we
lack data on the type and the severity of infections, we
TABLE 1. Percentage of antibiotic prescriptions with point of care per region in patients with health consumptions above the
deductible
Antibiotic group (number
of prescriptions/number of physicians) Region
Percentage of tests
CRP
Leucocyte
counts
Pharyngeal
swaba Urineb Radiographc Anye
Amoxicillin and amoxicillin-clavulanate
(58 550/5274)
CH totald 26 25 4 8 08 34
NW CH 31 29 3 8 9 38
East CH 33 31 3 9 10 42
Zurich 33 31 4 10 8 41
Midland 25 23 4 7 8 33
Central CH 36 34 4 10 10 44
Ticino 15 14 3 5 7 23
Lake Geneva 7 08 3 5 5 14
Other betalactams (15 100/2972) CH totald 24 23 5 7 9 34
NW CH 32 29 6 6 10 40
East CH 32 31 7 11 7 45
Zurich 42 38 6 9 10 50
Midland 23 21 5 7 10 33
Central CH 41 41 6 11 12 54
Ticino 20 19 5 6 8 29
Lake Geneva 06 7 5 5 6 16
Doxycycline (8041/2347) CH totald 21 22 01 11 6 31
NW CH 23 24 2 7 7 30
East CH 23 23 1 12 7 34
Zurich 32 32 1 14 6 42
Midland 17 17 1 12 6 28
Central CH 22 23 1 12 6 32
Ticino 12 12 0 7 6 18
Lake Geneva 6 8 1 6 9 14
Fluoroquinolones (76 423/5363) CH totald 24 24 1 41 5 57
NW CH 26 26 1 41 6 58
East CH 27 29 0 46 5 64
Zurich 30 29 01 45 6 63
Midland 23 22 0 43 4 57
Central CH 31 31 1 40 7 61
Ticino 18 18 0 32 6 45
Lake Geneva 9 12 0 33 4 40
Macrolides (40 230/4802) CH totald 34 31 4 4 13 40
NW CH 41 37 5 4 14 46
East CH 41 38 4 4 13 47
Zurich 48 43 5 5 15 52
Midland 30 26 4 3 12 36
Central CH 47 42 5 5 15 53
Ticino 20 15 3 2 08 25
Lake Geneva 7 8 3 2 09 14
Trimethoprim-sulfamethoxazole
(12 295/3187)
CH totald 15 17 1 43 3 52
NW CH 12 15 1 43 3 50
East CH 16 19 0 45 3 56
Zurich 20 22 1 43 4 56
Midland 12 16 1 49 2 56
Central CH 21 23 0 45 4 60
Ticino 9 15 0 36 2 44
Lake Geneva 5 7 1 28 3 32
NW, northwest; CH, Switzerland.
aTested for Streptococci group A either by antigen test or by culture.
bUrine analysis and culture.
cAny type of radiograph.
dNot standardized for age and gender.
ePerformed in a time window of 7 days prior to 2 days following an issued prescription.
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cannot rule out such bias. Because health insurers in Switzer-
land reimburse physicians for ofﬁce-based laboratory tests,
there exists an economic incentive to use such tests. Issues
of liability due to complications may be another reason for
laboratory testing or patients may request testing to exclude
a serious infection. Patient pressure has been reported as an
important factor in patient referral and additional clinical
investigations, even when general practitioners judge the
need for such activities as not high [19].
Previous observational studies from Scandinavia have
shown a reduction in antibiotic prescriptions with the use of
CRP in primary care [20,21]. Whether a diagnostic test leads
to fewer antibiotic prescriptions without compromising
patient outcome is ideally best addressed in a clinical trial
evaluating two or more diagnostic strategies and their clinical
consequences for patient-relevant outcomes [22]. Trials con-
ducted in primary care and in emergency departments found
no reduction of antibiotic prescriptions for respiratory tract
infections with CRP testing [23–25], whereas one trial using
a more complex intervention with general practitioner train-
ing and use of CRP tests did show a reduction of antibiotic
prescription in patients with acute bronchitis [7].
Our study has several limitations. The population served
by the Helsana Group was slightly older and generated
higher costs than the average Swiss population. Therefore,
antibiotic consumption eventually may be higher in this popu-
lation than in the remaining Swiss population. In some areas
with self-dispensing physicians, patients with high deductibles
may not send the invoice to the health insurer but rather
pay them directly. From previous unpublished studies, we
estimate that 2–3% of all invoices are directly paid and not
reimbursed by the Helsana Group [26]. Social health insurers
do not get full and accurate information regarding the exact
diagnosis from the physician-patient encounter. Therefore,
we were unable to link antibiotic prescriptions and the use
of point of care tests to a particular diagnosis. Data from a
Swedish surveillance study indicate that CRP in primary care
is overwhelmingly used in respiratory tract infections [27]. In
addition, our study lacks detail regarding important charac-
teristics of the study population that goes beyond crude esti-
mates of age and gender distributions.
In conclusion, this study shows that the regions of the
northwest and east of Switzerland have one of the lowest
antibiotic prescription rates in ambulatory care in Europe.
Swiss regions with higher prescription rates show higher sea-
sonal variability in antibiotic use. The use of any point of care
test was associated with an important reduction in the pre-
scription of the most frequently used antibiotics. Our ﬁnd-
ings need conﬁrmation from other countries and indicate
that more research for new point of care tests and better
integration of already existing point of care tests into pri-
mary care may be a promising strategy to reduce antibiotic
consumption and thereby the emergence of antibiotic resis-
tance in the community.
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TABLE 2. Ratio of the number of antibiotic prescriptions and number of patients of primary care physicians for antibiotic
compounds according to point of care tests and patient characteristics
Amoxicillin and
amoxicillin-clavulanate Fluoroquinolones Macrolides Other betalactams
Trimethoprim-
sulfamethoxazole Doxycycline
Coefﬁcients (95% CI)a [P-value]
Any radiographb 1.03 (0.91, 1.18)
[0.604]
1.01 (0.90, 1.12)
[0.926]
0.91 (0.81, 1.01)
[0.087 ]
0.81 (0.65, 1)
[0.046 ]
0.71 (0.45, 1.12)
[0.142]
0.95 (0.63, 1.45)
[0.822]
Any POCTc 0.79 (0.74, 0.84)
[<0.001]
0.68 (0.65, 0.72)
[<0.001]
0.76 (0.72, 0.81)
[<0.001]
0.63 (0.56, 0.71)
[<0.001]
0.68 (0.6, 0.77)
[<0.001]
0.91 (0.73, 1.13)
[0.387]
Female patients 0.77 (0.74, 0.79)
[<0.001]
1.02 (1.00, 1.05)
[0.105]
0.85 (0.82, 0.89)
[<0.001 ]
0.79 (0.73, 0.85)
[<0.001]
0.76 (0.68, 0.84)
[<0.001]
0.77 (0.68, 0.87)
[<0.001]
Age groupd 1.30 (1.26, 1.35)
[<0.001]
1.60 (1.56, 1.64)
[<0.001]
1.11 (1.06, 1.16)
[<0.001]
1.26 (1.17, 1.36)
[<0.001]
1.47 (1.35, 1.60)
[<0.001]
1.18 (1.03, 1.34)
[0.014]
Adjusted R2 0.110 0.188 0.046 0.113 0.159 0.039
aBack-transformed coefﬁcients with conﬁdence intervals (CI) for antibiotic prescriptions: coefﬁcients >1 indicate more and coefﬁcients <1 less prescriptions.
Regression model: log(Yi)  b0 + b1 · AnyXRayi + b2 · AnyPocti + b3 · genderi + b4 · agei + i, where: Yi, number of prescriptions/number of patients; i, antibiotic group,
physician and patient group; AnyPocti, number POCTi/number of antibiotic prescriptionsi 0 £ Any POCT £ 1; genderi, [male, female].
bAny radiographi, number of radiographs (including all radiographs)i/number of antibiotic prescriptionsi, 0 £ Any radiograph £ 1.
cPOCT, point of care test.
dAgei [18–64, 65+].
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